CompletedNCT03232203
Evaluating the Effectiveness of STRIMVELIS Risk Minimization Measures (RMMs)
Studying Severe combined immunodeficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fondazione Telethon
- Principal Investigator
- Fondazione TelethonFondazione Telethon
- Intervention
- STRIMVELIS(drug)
- Enrollment
- 16 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2021
Study locations (1)
- Ospedale San Raffaele - Telethon Institute for Gene Therapy (OSR-TIGET), Milan, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03232203 on ClinicalTrials.govOther trials for Severe combined immunodeficiency
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05651113The Experience of Screening for SCIDKing's College London
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT01852370Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency DiseasesPaul Szabolcs
- ENROLLING BY INVITATIONNCT01186913Natural History Study of SCID DisordersNational Institute of Allergy and Infectious Diseases (NIAID)